Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China flag China · Delayed Price · Currency is CNY
6.46
+0.01 (0.16%)
Feb 27, 2026, 3:04 PM CST

Beijing SL Pharmaceutical Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
6,6377,67410,4698,44511,10610,376
Market Cap Growth
-9.27%-26.69%23.97%-23.96%7.03%-23.19%
Enterprise Value
5,6916,7629,6077,40410,1959,699
Last Close Price
6.467.459.967.9510.359.57
PE Ratio
81.65-25.1236.0326.0728.45
Forward PE
-12.3512.3512.3512.3512.35
PS Ratio
11.4711.6210.288.049.149.32
PB Ratio
1.161.381.801.542.092.08
P/TBV Ratio
1.321.572.051.712.302.28
P/FCF Ratio
--43.2937.3148.7764.90
P/OCF Ratio
72.2834.0322.7521.6623.9024.95
PEG Ratio
-1.771.771.771.771.77
EV/Sales Ratio
9.8410.249.437.058.398.72
EV/EBITDA Ratio
40.8337.4426.2828.7932.6840.51
EV/EBIT Ratio
-244.5843.6551.5448.0264.68
EV/FCF Ratio
-19.92-39.7232.7144.7760.66
Debt / Equity Ratio
----00.00
Debt / EBITDA Ratio
----0.010.02
Debt / FCF Ratio
----0.010.03
Net Debt / Equity Ratio
-0.17-0.35-0.37-0.26-0.31-0.29
Net Debt / EBITDA Ratio
-6.84-10.98-5.84-5.65-5.24-6.00
Net Debt / FCF Ratio
3.3416.26-8.82-6.42-7.17-8.99
Asset Turnover
0.100.110.170.180.220.21
Inventory Turnover
0.691.091.341.201.551.52
Quick Ratio
5.077.276.356.026.206.07
Current Ratio
12.378.607.076.927.077.01
Return on Equity (ROE)
1.47%-1.32%7.35%4.23%8.17%7.37%
Return on Assets (ROA)
-0.20%0.28%2.26%1.54%2.38%1.76%
Return on Invested Capital (ROIC)
-0.45%0.76%5.10%3.28%5.40%4.07%
Return on Capital Employed (ROCE)
-0.30%0.50%3.70%2.60%3.90%3.00%
Earnings Yield
1.26%-0.97%3.98%2.78%3.84%3.52%
FCF Yield
-4.30%-1.59%2.31%2.68%2.05%1.54%
Dividend Yield
0.31%0.27%1.51%1.26%0.97%1.04%
Payout Ratio
24.53%-24.65%43.83%24.17%56.44%
Buyback Yield / Dilution
-4.23%-4.11%0.28%1.90%-2.55%2.19%
Total Shareholder Return
-3.92%-3.84%1.78%3.16%-1.58%3.23%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.